Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.54 USD | +4.14% | -7.71% | +133.44% |
05-28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
05-15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+133.44% | 838M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.47% | 16.37B | |
+2.23% | 13.58B | |
+27.13% | 11.66B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Transcript : Arcutis Biotherapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024